Influence of Chlorine or Fluorine Substitution on the Estrogenic Properties of 1-Alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles
摘要:
In continuation of Our previous work, several 1- alkyl-2,3,5-tris(4-hydroxyphenyl)aryl-1H-pyrroles with chlor-Me or fluorine substituents in the aryl residues were synthesized and tested for estrogen receptor (ER) binding at isolated ER alpha/ER beta. receptors (HAP assay), and. in trans activation assays using ER alpha-positive MCF-7/2a as well as U2-OS/ER alpha and U2-OS/ER beta cells. In the competition experiment at ER alpha the compounds displayed very high relative binding-affinities of up to 37% (determined for 8m) but with restricted subtype selectivity (e.g., ER alpha/ER beta (8ma) = 9). The highest estrogenic potency in ER alpha-positive MCP-7/2a cells was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-prolayl-1H-pyriole 8m (EC50 = 23 nM), while in U2-OS/ER alpha cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1H propyl-1H pyrrole 8b (EC50 = 0.12 nM) was the Most potent agonist, only 30 fold less active than estradiol (E2, EC50 = 0.004 nM). In U2-OS/ER beta cells for all pyrroles no transactivation could be observed, which indicates that they are selective ER alpha agonists in Cellular systems.
Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents
申请人:Freie Universität Berlin
公开号:EP1889617A1
公开(公告)日:2008-02-20
The present invention provides 5-membered heterocycles, preferably pyrroles, furans and thiophenes, with three phenyl moieties wherein at least one of the three phenyl moieties is substituted with halogen or trihalomethyl. The compounds of the invention show antiproliferative effects and inhibitory effects on cyclooxygenases (COX-1 and COX-2). Therefore the invention is also directed to the use of said compounds for the manufacture of a pharmaceutical composition for prevention and treatment of cancer and/or inflammatory diseases. The invention further concerns a method for treating cancer or an inflammatory disease, which comprises the step of administering to a patient suffering from that disease a therapeutically effective amount of at least one of said compounds.
[EN] TRIPHENYL MODIFIED 5-MEMBERED HETEROCYCLES AND THEIR USE AS ANTICANCER AND ANTIINFLAMMATORY AGENTS<br/>[FR] HÉTÉROCYCLES À 5 CHAÎNONS MODIFIÉS PAR TROIS NOYAUX PHÉNYLE ET LEUR UTILISATION EN TANT QU'AGENTS ANTICANCÉREUX ET ANTI-INFLAMMATOIRES
申请人:UNIV BERLIN FREIE
公开号:WO2008006626A1
公开(公告)日:2008-01-17
[EN] The present invention provides 5-membered heterooycles, preferably pyrrole furans and thiophenes, with three phenyl moieties wherein at least one of the three Phenyl moieties is substituted with halogen and alkoxy, halogen and hydrox trihalomethy, and alkoxy, trihatomethyl and hydroxy or halogen and alky, an wherein a second phenyl moiety is substituted with at least hydroxy or alkoxy The compounds of the invention show antiproliferative effects and inhibitory effects on cyclooxygenases (COX-1 and COX-2). Therefore the invention is also directed to the use of said compounds for the manufacture of a pharmaceutic composition for prevention and treatment of cancer and/or inflammatory diseases The invention further concerns a method for treating cancer or an inflammator disease, which comprises the step of administering to a patient suffering from that disease a therapeutically effective amount of at least one of said compounds. [FR] La présente invention concerne des hétérocycles à 5 chaînons, de préférence des cycles pyrrole, furane et thiophène, comportant trois entités phényle, au moins une des trois entités phényle étant substituée par l'halogène et l'alcoxy, l'halogène et l'hydroxy trihalométhyle, et l'alcoxy, le trihalométhyle et l'hydroxy ou l'halogène et l'alkyl, une seconde entité phényle étant substituée par au moins l'hydroxy ou l'alcoxy. Les composés de l'invention présentent des effets antiprolifératifs et des effets inhibiteurs sur les cyclooxygénases (COX-1 et COX-2). Par conséquent, l'invention concerne également l'utilisation desdits composés pour la fabrication d'une composition pharmaceutique pour la prévention et le traitement du cancer et/ou de maladies inflammatoires. L'invention concerne en outre un procédé de traitement du cancer ou d'une maladie inflammatoire, comprenant l'étape d'administration à un patient souffrant d'une telle maladie d'une quantité efficace du point de vue thérapeutique d'au moins un desdits composés.
Influence of Chlorine or Fluorine Substitution on the Estrogenic Properties of 1-Alkyl-2,3,5-tris(4-hydroxyphenyl)-1<i>H</i>-pyrroles
In continuation of Our previous work, several 1- alkyl-2,3,5-tris(4-hydroxyphenyl)aryl-1H-pyrroles with chlor-Me or fluorine substituents in the aryl residues were synthesized and tested for estrogen receptor (ER) binding at isolated ER alpha/ER beta. receptors (HAP assay), and. in trans activation assays using ER alpha-positive MCF-7/2a as well as U2-OS/ER alpha and U2-OS/ER beta cells. In the competition experiment at ER alpha the compounds displayed very high relative binding-affinities of up to 37% (determined for 8m) but with restricted subtype selectivity (e.g., ER alpha/ER beta (8ma) = 9). The highest estrogenic potency in ER alpha-positive MCP-7/2a cells was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-prolayl-1H-pyriole 8m (EC50 = 23 nM), while in U2-OS/ER alpha cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1H propyl-1H pyrrole 8b (EC50 = 0.12 nM) was the Most potent agonist, only 30 fold less active than estradiol (E2, EC50 = 0.004 nM). In U2-OS/ER beta cells for all pyrroles no transactivation could be observed, which indicates that they are selective ER alpha agonists in Cellular systems.